大健康国际2023/24 年度报告

Stock Code: 2211(Incorporated in the Cayman Islands with limited liability 頁次Company Profile公司簡介2Corporate Information公司資料4Financial Highlights財務摘要7Chairman’s Statement主席報告8Management Discussion and Analysis管理層討論及分析13Environmental, Social and Governance Report環境、 社會及管治報告26Report of the Directors董事會報告45Corporate Governance Report企業管治報告66Directors and Senior Management董事及高級管理層89Independent Auditor’s Report獨立核數師報告95Consolidated Balance Sheet合併資產負債表107Consolidated Statement of Comprehensive Income合併綜合收益表109Consolidated Statement of Changes in Equity合併權益變動表111Consolidated Cash Flow Statement合併現金流量表113Notes to the Consolidated Financial Statements合併財務報表附註115Financial Summary財務資料概要259 COMPANY PROFILE公司簡介 Universal Health International Group Holding Limited (Stockcode: 2211) (the “Company”, together with its subsidiaries, the“Group”) and its subsidiaries aims at huge market opportunitiesin the universal health industry, strives to be international brandoperator of universal health and become a leading practitioner ofthe strategy of “Internet + Universal Health” as well as a pioneerof the development of ecology in the industry chain by way offinance and capital. 大健康國際集團控股有限公司（「本公司」，連同其附屬公司，「本集團」及其附屬公司（「本集團」），股份代號：2211），瞄準大健康領域巨大的市場機會，傾力打造國際大健康品牌運營商，並成為「互聯網+大健康」戰略的領先實踐者，和憑藉金融與資本的方式發展產業鏈生態圈的行業倡領者。 本公司是中華人民共和國（「中國」）東北地區領先的醫藥零售商及分銷商之一。本集團擁有中國東北地區卓越的醫藥零售連鎖網路，為中國東北地區最大的民營醫藥分銷商之一。截至本年報日期，本集團擁有203家零售藥店，主要位於中國東北地區，在全國擁有約1,515名活躍分銷商，在職員工1,286名，並於石家莊、瀋陽、哈爾濱及佳木斯設置了四個較大規模的物流儲運中心，構建了覆蓋全國和覆蓋中國東北地區的優質配送體系。 The Company is one of the leading pharmaceutical retailer anddistributor in the Northeast of the People’s Republic of China (the“PRC” or “China”). The Group has distinguished pharmaceuticalretail chain network in the Northeast China and it is also the largestprivately operated pharmaceutical distributor in the NortheastChina. As of the date of this annual report, the Group operated203 retail pharmacies, mainly located in the Northeast China, andhad approximately 1,515 active distributors and 1,286 full-timestaff. In addition, the Group has set up four large-scale logisticsstorage centers in Shijiazhuang, Shenyang, Harbin and Jiamusi,and has established a high-quality distribution system across thecountry and covering the northeastern region of the PRC. 作為基礎業務板塊，本集團的醫藥零售及分銷（含進出口貿易）的主要經營產品種類，包括處方藥、非處方藥（中成藥、化學藥製劑、抗生素、生化藥品）、傳統中藥飲片、生物製品、蛋白同化製劑、肽類激素、血液製品、消毒用品、醫療器械、計生用品（避孕藥品和用具）、預包裝食品、乳製品（含嬰幼兒配方乳粉）、保健食品、保健用品、定型包裝化妝品及日用百貨等。 As a basic business segment, the Group’s main product categoriesfor pharmaceutical retail and distribution (including import andexport trade) include prescribed drugs, non-prescribed drugs(Chinese patent medicines, chemical preparations, antibioticsand biochemical drugs), traditional Chinese medicine decoctionpieces, biological products, protein assimilation preparations,peptide hormones, blood products, disinfection products, medicalequipment, family planning supplies (contraceptives and utensils),prepackaged foods, dairy products (including infant formula milkpowder), nutritional foods, health care products, stereotypedpackaging cosmetics, daily necessities, etc. The Group will continue leveraging on the core advantagesof branded products, expanding the scope of cooperation onbranded products, leveraging on business institute training, andproviding more value-added service to employees, customersand consumers. The Group also enriches the product mix byintroducing more health care products based on the expertise inpharmaceutical retail and distribution, so as to promote the conceptof the universal health industry. Meanwhile, the Group activelyexplores upstream ecological chain, covering the construction forChinese herbal medicines base and the production of botanicalcapsule. 本集團繼續發揮品牌產品的核心優勢，擴大品牌產品合作範圍，借助商學院的課程培訓，為員工、客戶及消費者提供更多的增值服務，致力於藥品零售及分銷的專業基礎上，使更多健康類產品進入銷售管道，推行大健康行業理念。同時，本集團積極拓展上游生態鏈，延伸到中藥材種植基地建設和植物膠囊生產領域。 本集團在網路藥店、跨境電商、網紅引流及其他「互聯網+」領域作積極探索，並倡導「專業+」理念，引進「平台+」發展理念，借助行業優勢維護上下游生態圈，應對實體經濟「新常態」，在行業中率先實行產業升級及數字化轉型。 The Group actively explores online pharmacies, cross-bordere-commerce, influencer marketing and other “Internet+” areas,and advocates the concept of “Specialization+” and introducesthe development concept of “Platform+”. Furthermore, the Groupmaintains upstream and downstream ecosystem leveraging onindustry advantage to cope with the situation of “New Norm” inreal economy, and takes the lead in upgrading and digitalizedtransformation of the industry. CORPORATE INFORMATION公司資料 BOARD OF DIRECTORS 董事會 執行董事： Executive Directors: 初川富先生（主席，首席執行官及首席營運官）金東昆先生（副主席）趙澤華先生 Mr. Chu Chuanfu(Chairman,Chief Executive Officer and Chief Operation Officer)Mr. Jin Dongkun(Vice Chairman)Mr. Zhao Zehua 獨立非執行董事： Independent Non-executive Directors: 鄭雙慶先生江素惠女士鄒海燕先生 Mr. Cheng Sheung HingMs. Chiang Su Hui SusieMr. Zou Haiyan 審核委員會 AUDIT COMMITTEE 鄒海燕先生（主席）鄭雙慶先生江素惠女士 Mr. Zou Haiyan(Chairman)Mr. Cheng Sheung HingMs. Chiang Su Hui Susie REMUNERATION COMMITTEE 薪酬委員會 鄭雙慶先生（主席）江素惠女士金東昆先生 Mr. Cheng Sheung Hi